We are live on ! Find out more
HQL

abrdn Life Sciences Investors

74 hedge funds and large institutions have $149M invested in abrdn Life Sciences Investors in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 28 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $136M → $149M (+$12.5M)

0.98% more ownership

Funds ownership: 35.17%36.15% (+0.98%)

9% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 11

1% less funds holding

Funds holding: 7574 (-1)

29% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 28

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
74
Holders Change
-1
Holders Change %
-1.33%
% of All Funds
1.06%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
10
Increased
20
Reduced
28
Closed
11
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
RL
76
RPO LLC
Connecticut
-$3.67M -259,275 Closed
BFM
77
Boothbay Fund Management
New York
-$1.65M -116,674 Closed
AW
78
Atlas Wealth
Ohio
-$1.19M -83,322 Closed
LCM
79
Landscape Capital Management
New Jersey
-$786K -55,453 Closed
GC
80
Guggenheim Capital
Illinois
-$390K -27,505 Closed
CA
81
Cornerstone Advisors
North Carolina
-$317K -22,339 Closed
IFG
82
Independent Financial Group
California
-$144K -10,165 Closed
ACA
83
Atlas Capital Advisors
Wyoming
-$1.96K -138 Closed
RCM
84
Raleigh Capital Management
North Carolina
-$1.47K -104 Closed
CIBC Private Wealth Group
85
CIBC Private Wealth Group
Georgia
-$416 -29 Closed
Fidelity Investments
86
Fidelity Investments
Massachusetts
-$28 -2 Closed

HQL Hedge Fund Activity: Q3 2024 in Review

74 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q3 2024, worth a combined $149M — up 9.2% from $136M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of HQL and 10 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 20 added.

The largest buyer was Penserra Capital Management, opening a new position worth an estimated $11.7M. The largest seller was RPO LLC, exiting entirely with an estimated $3.67M sold.

  • 74 institutional investors held abrdn Life Sciences Investors (HQL) as of Q3 2024, down from 75 in Q2 2024.
  • Funds reported $149M of abrdn Life Sciences Investors stock for Q3 2024, up 9.2% quarter-over-quarter.
  • 10 funds opened new abrdn Life Sciences Investors positions in Q3 2024 and 11 closed out, a net change of -1 holder.
  • The largest abrdn Life Sciences Investors buyer in Q3 2024 was Penserra Capital Management, an estimated $11.7M added.
  • The largest abrdn Life Sciences Investors seller in Q3 2024 was RPO LLC, an estimated $3.67M sold.

Based on aggregated 13F filings for Q3 2024.